News

    BioStock article: Aptahem’s new CMO on her role and vision

    2022-06-20

    BioStock published an article on 17 June 2022 about Aptahem, which can be read in full below. Aptahem has appointed Dr Ingela Hallberg as the new Medical Director. The company is thus putting another piece of the puzzle in...

    Read More

    Aptahem appoints Ingela Hallberg as new CMO

    2022-06-01

    Aptahem (publ) announces today that Ingela Hallberg has been appointed new Chief Medical Officer (CMO) in the company as of 1 June 2022. Ingela has long and solid experience from the pharmaceutical industry where she has held senior management...

    Read More

    BioStock article: Aptahem signs agreement with CRO for phase I studies

    2022-05-23

    BioStock published an article on 23 May 2022 about Aptahem, which can be read in full below. Aptahem has entered into an agreement with a clinical contract research organisation in the Netherlands for the implementation of the upcoming phase...

    Read More

    Aptahem enters agreement with international clinical CRO for phase 1 studies with Apta-1

    2022-05-17

    Aptahem (publ) announces today that the company has signed an agreement with the clinical contract research organization (CRO) The Centre for Human Drug Research (CHDR) in the Netherlands to perform the upcoming phase 1 studies with Apta-1. By entering...

    Read More

    Aptahem enters new consortium financed by the KK Foundation

    2022-05-09

    Aptahem (publ) today announce that the company enters a consortium together with Örebro University, Attgeno AB, BioReperia AB, Buzzard Pharmaceuticals AB, Lipum AB, Thermo Fisher Scientific och Toleranzia AB. The newly established consortium aims to evaluate new treatments to...

    Read More

    BioStock article: Aptahem on the latest news

    2022-03-09

    BioStock published an article on 9 March 2022 about Aptahem, which can be read in full below. Aptahem has communicated several positive news lately. Recently, the company received patent protection in Japan for patent family 2 regarding the drug...

    Read More

    Aptahem reports prepared GMP certified Apta-1 for preparation of clinical studies

    2022-03-07

    Aptahem announces today that the production of Good Manufacturing Practice (GMP) manufacturing of the drug candidate Apta-1 successfully has been prepared by the collaboration partner LGC Biotechnologies in the USA, according to timeplan. The GMP manufactured Apta-1 will be...

    Read More

    Aptahem reports additional positive biological effect in a Corona virus-induced acute lung injury model treated with Apta-1

    2022-02-21

    Aptahem can today announce that in addition to previously reported positive preliminary data, the Toronto team has, from further studies, found essential positive effects in a Corona virus challenge induced Acute Lung Injury model with Apta-1 treatment. Studies show...

    Read More

    Aptahem receives patent protection in Japan for patent family 2

    2022-02-16

    Aptahem AB (publ) announces today that the company has received patent protection in Japan for patent family 2 from the Japanese Patent Office (JPO). With JPO’s approval of patent application 2020-519806, the protection of the company’s drug candidate Apta-1...

    Read More

    BioStock article: Aptahem recruits to key positions before clinical studies

    2022-02-04

    BioStock published an article on 4 February 2022 about Aptahem, which can be read in full below. Aptahem has recently recruited to fill three key positions ahead of the phase I studies planned with sepsis candidate Apta-1. Karin Aschan...

    Read More